Features of immunometabolic depression as predictors of antidepressant treatment outcomes: pooled analysis of four clinical trials.
Sarah R VreijlingCherise R Chin FattLeanne M WilliamsAlan F SchatzbergTim UsherwoodCharles B NemeroffA John RushRudolf UherKatherine J AitchisonOle Köhler-ForsbergMarcella RietschelMadhukar H TrivediManish K JhaBrenda W J H PenninxAartjan T F BeekmanRick JansenFemke LamersPublished in: The British journal of psychiatry : the journal of mental science (2024)
Depressive symptoms of people with more IMD features improved less when treated with antidepressants. However, clinical relevance is limited owing to small effect sizes in inconsistent associations. Whether these patients would benefit more from treatments targeting immunometabolic pathways remains to be investigated.
Keyphrases
- depressive symptoms
- clinical trial
- end stage renal disease
- newly diagnosed
- major depressive disorder
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- sleep quality
- social support
- physical activity
- mass spectrometry
- patient reported outcomes
- open label
- atomic force microscopy
- study protocol